Table 1. Characteristics of Children With Invasive Pneumococcal Disease in the French Hospital Medical Information Database.
Characteristic | Patients, No. (%) | ||||||
---|---|---|---|---|---|---|---|
PCV7 perioda | Transition period 1b | PCV13 period | Transition period 2e | NPI periodf | All study periods, including transition periodsg | ||
Earlyc | Lated | ||||||
Total patients, No. | 1445 | 416 | 1031 | 1987 | 40 | 194 | 5113 |
Age, median (IQR), yh | 1.0 (0.6-4.0) | 1.0 (0.7-4.0) | 2.0 (0.6-5.0) | 1.0 (0.6-4.0) | 1.0 (0.5-2.0) | 1.0 (0.6-3.0) | 1.0 (0.6-4.0) |
Sex | |||||||
Male | 853 (59.0) | 231 (55.5) | 575 (55.8) | 1170 (58.9) | 22 (55.0) | 108 (55.7) | 2959 (57.9) |
Female | 592 (41.0) | 185 (44.5) | 456 (44.2) | 817 (41.1) | 18 (45.0) | 86 (44.3) | 2154 (42.1) |
Meningitis | 703 (48.7) | 211 (50.7) | 560 (54.3) | 1029 (51.8) | 23 (42.5) | 72 (37.1) | 2598 (50.8) |
Bacteremia without meningitis | 742 (51.3) | 205 (48.3) | 471 (45.7) | 958 (48.2) | 17 (57.5) | 122 (62.9) | 2515 (49.2) |
Deaths | 60 (4.2) | 30 (7.2) | 56 (5.4) | 68 (3.4) | 1 (2.5) | 6 (3.1) | 221 (4.3) |
Abbreviations: NPI, nonpharmaceutical intervention; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
The PCV7 period was from January 1, 2007, to May 31, 2010.
Transition period 1 was from June 1, 2010, to May 31, 2011.
The early PCV13 period was from June 1, 2011, to May 31, 2014.
The late PCV13 period was from June 1, 2014, to February 29, 2020.
Transition period 2 was from March 1 to 31, 2020.
The NPI period was from April 1, 2020, to March 31, 2021.
Includes all periods from June 1, 2010, to May 31, 2021 (including transition periods).
Age was only available in rounded-down years for children older than 1 year in the French hospital medical information database (Programme de Medicalisation des Systèmes d’Information).